Abstract:Abstract Tumor cells transform into endothelial cells by epithelial-to-mesenchymal transition, which is characterized by vasculogenic mimicry (VM). VM not only accelerates tumor progression but also increases drug-induced resistance. However, very little is currently known about the molecular determinants that enable VM. Targeting VM might bring a new breakthrough in cancer treatment. Thrombin is the key enzyme of the blood coagulation system and could contribute to tumor progression. Nevertheless, the association between thrombin and VM formation remains largely unknown. We found that VM was associated with the overall survival of non-small-cell lung cancer (NSCLC) patients, and that thrombin expression was closely related to VM formation. This research revealed that thrombin induced VM formation via PAR-1-mediated NF-κB signaling cascades. The novel thrombin inhibitors r-hirudin and DTIP inhibited VM formation and spontaneous metastases in subcutaneous tumors. Clinical pathological analysis confirmed that NSCLC patients with thrombin-positive/PAR-1-high expression had the poorest prognosis and were the most likely to form VM. The promotional activity of thrombin in VM formation and tumor metastasis was abolished in PAR-1-deficient NSCLC cells. The EGFR inhibitor gefitinib had no effect on VM and increased VEGF expression in tumors. The combination therapy of DTIP and gefitinib achieved a better therapeutic effect than either agent alone. This study is the first to illustrate that thrombin substantially contributes, together with PAR-1, to VM formation and to illustrate that VM might be a target of r-hirudin and DTIP to suppress tumor progression. The anticoagulants r-hirudin and DTIP could be employed for antitumor therapy. Combination therapy with DTIP with an EGFR inhibitor might achieve superior therapeutic effects.

NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6Clow Monocytes/Macrophages Differentiation to Accelerate Thrombolysis

NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C<SUP>low</SUP> Monocytes/Macrophages Differentiation to Accelerate Thrombolysis

‘Adhesion and Release’ Nanoparticle-Mediated Efficient Inhibition of Platelet Activation Disrupts Endothelial Barriers for Enhanced Drug Delivery in Tumors

Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy

Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels

Combination of Tumour-Infarction Therapy and Chemotherapy Via the Co-Delivery of Doxorubicin and Thrombin Encapsulated in Tumour-Targeted Nanoparticles

Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis.

Responsively Aggregatable Sub-6 Nm Nanochelators Induce Simultaneous Antiangiogenesis and Vascular Obstruction for Enhanced Tumor Vasculature Targeted Therapy.

Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.

&Lt;em>n</em>-(3-hydroxymethyl-&beta;-carboline-1-yl-ethyl-2-yl)-l-phe: Development Toward a Nanoscaled Antitumor Drug Capable of Treating Complicated Thrombosis and Inflammation

Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models

Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.

Enhance Mitochondrial Damage by Nuclear Export Inhibition to Suppress Tumor Growth and Metastasis with Increased Antitumor Properties of Macrophages

Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy

Selective Eradication of Tumor Vascular Pericytes by Peptide-Conjugated Nanoparticles for Antiangiogenic Therapy of Melanoma Lung Metastasis.

Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation

Inhibition of Intrinsic Coagulation Improves Safety and Tumor-Targeted Drug Delivery of Cationic Solid Lipid Nanoparticles

Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis

Targeted Thrombolysis with Magnetic Nanotherapeutics: A Translational Assessment

Construction And Characterization Of A Truncated Tissue Factor-Coagulation-Based Composite System For Selective Thrombosis In Tumor Blood Vessels

Glycol-Split Heparin-Linked Prodrug Nanoparticles Target the Mitochondrion Apparatus for Cancer Metastasis Treatment.